疾病修饰治疗与多发性硬化患者COVID-19严重程度
该回顾性研究纳入844例疑似或确诊COVID-19的多发性硬化患者,评估免疫抑制和免疫调节治疗对COVID-19严重程度的影响。调整混杂因素后,抗CD20治疗与严重COVID-19风险增加相关(OR=2.37),近期使用甲泼尼龙也与更差结局相关(OR=5.24)。研究提示多数治疗安全性可接受,但需关注特定风险因素。
要点
- 抗CD20治疗与严重COVID-19风险增加独立相关(OR=2.37)。
- 近期(<1个月)使用甲泼尼龙与更差结局相关(OR=5.24)。
- 多数多发性硬化治疗在COVID-19中显示可接受的安全性。
核心结论
- 多发性硬化治疗总体安全性可接受,但抗CD20治疗和近期甲泼尼龙使用与严重COVID-19风险增加相关。
研究设计与样本
- 回顾性收集844例疑似(n=565)或确诊(n=279)COVID-19的多发性硬化患者数据,随访至死亡或康复。
主要发现
- 13例(1.54%)死亡,其中11例处于进展型多发性硬化阶段,8例未接受任何治疗。
- 调整区域、年龄、性别、进展型病程、EDSS、病程、BMI、合并症和近期甲泼尼龙使用后,抗CD20治疗与严重COVID-19风险增加相关(OR=2.37,95%CI=1.18-4.74,p=0.015)。
- 近期(<1个月)使用甲泼尼龙与更差结局相关(OR=5.24,95%CI=2.20-12.53,p=0.001)。
- 倾向评分加权分析和所有敏感性分析均证实上述结果。
临床怎么用
- 在COVID-19大流行期间,对多发性硬化患者使用抗CD20治疗或近期甲泼尼龙时需权衡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study was undertaken to assess the impact of immunosuppressive and immunomodulatory therapies on the severity of coronavirus disease 2019 (COVID-19) in people with multiple sclerosis (PwMS). METHODS: We retrospectively collected data of PwMS with suspected or confirmed COVID-19. All the patients had complete follow-up to death or recovery. Severe COVID-19 was defined by a 3-level variable: mild disease not requiring hospitalization versus pneumonia or hospitalization versus intensive care unit (ICU) admission or death. We evaluated baseline characteristics and MS therapies associated with severe COVID-19 by multivariate and propensity score (PS)-weighted ordinal logistic models. Sensitivity analyses were run to confirm the results. RESULTS: Of 844 PwMS with suspected (n = 565) or confirmed (n = 279) COVID-19, 13 (1.54%) died; 11 of them were in a progressive MS phase, and 8 were without any therapy. Thirty-eight (4.5%) were admitted to an ICU; 99 (11.7%) had radiologically documented pneumonia; 96 (11.4%) were hospitalized. After adjusting for region, age, sex, progressive MS course, Expanded Disability Status Scale, disease duration, body mass index, comorbidities, and recent methylprednisolone use, therapy with an anti-CD20 agent (ocrelizumab or rituximab) was significantly associated (odds ratio [OR] = 2.37, 95% confidence interval [CI] = 1.18-4.74, p = 0.015) with increased risk of severe COVID-19. Recent use (<1 month) of methylprednisolone was also associated with a worse outcome (OR = 5.24, 95% CI = 2.20-12.53, p = 0.001). Results were confirmed by the PS-weighted analysis and by all the sensitivity analyses. INTERPRETATION: This study showed an acceptable level of safety of therapies with a broad array of mechanisms of action. However, some specific elements of risk emerged. These will need to be considered while the COVID-19 pandemic persists. ANN NEUROL 2021;89:780-789.
引用
- Sormani MP, De Rossi N, Schiavetti I, et al. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. Ann Neurol. 2021. PMID: 33480077. doi:10.1002/ana.26028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。